102308-48-5

Usage

Uses

Used in Pharmaceutical Industry:
DIMETHYL-(2-PIPERIDIN-4-YL-ETHYL)-AMINE is used as a precursor for the synthesis of bioactive compounds and nucleophiles for their potential interaction with different biological systems and properties. Its role in the development of pharmaceuticals is attributed to its ability to act as a building block for creating new drugs with specific therapeutic effects.
The detailed properties such as melting point, boiling point, density, and solubility of DIMETHYL-(2-PIPERIDIN-4-YL-ETHYL)-AMINE would vary based on its purity, concentration, and other factors. The chemical safety, toxicity, or potential health effects of DIMETHYL-(2-PIPERIDIN-4-YL-ETHYL)-AMINE are not readily available and would need to be evaluated by relevant health organizations to ensure its safe use in pharmaceutical applications.

InChI:InChI=1/C9H20N2/c1-11(2)8-5-9-3-6-10-7-4-9/h9-10H,3-8H2,1-2H3

Upstream product

• 38223-06-2 4-<2-(dimethylamino)ethyl>pyridine 
• 622-26-4 4-(2-Hydroxyethyl)piperidine 
• 98-88-4 benzoyl chloride 
• 100-43-6 4-vinylpyridine 

Downstream Products

• 1192684-39-1 2-[3-(3-chlorophenyl)-7-{4-[2-(dimethylamino)ethyl]-1-piperidinyl}-1-oxopyrrolo[1,2-a]pyrazin-2(1H)-yl]-N-(1-methylethyl)acetamide 
• 63916-14-3 4-[2-(dimethyl-propyl-ammonio)-ethyl]-1-methyl-1-propyl-piperidinium; diiodide 
• 63887-38-7 1-ethyl-4-[2-(ethyl-dimethyl-ammonio)-ethyl]-1-methyl-piperidinium; diiodide 
• 63887-35-4 1,1-dimethyl-4-(2-trimethylammonio-ethyl)-piperidinium; diiodo 

Relevant academic research and scientific papers

Benzenesulphonamide derivatives, method for production and use thereof for treatment of pain

The present invention concerns novel benzenesulphonamide compounds, defined by formula I and the description, their method of preparation and their use in therapy.

Therapeutic agents

Compounds of formula I STR1 and pharmaceutically acceptable salts thereof in which R1, R2 and R3 independently represent hydrogen, hydroxy, halo, alkyl or alkoxy; ALK1 represents a C2-6 alkylene chain optionally substituted by one or more C1-2 alkyl groups; Y represents a piperidine ring which is attached through nitrogen to ALK1 ; R4 represents hydrogen or a C1-4 alkyl group; the broken line in --- represents a bond, or is absent and the free valency on Y is taken up by hydrogen and the free valency on CR4 is taken up by hydrogen or a C1-4 alkyl group; ALK2 is absent or represents a C1-4 alkylene chain optionally substituted by one or more C1-2 alkyl groups; and R5 and R6 independently represent hydrogen, alkyl, phenyl, alkyl (optionally substituted) or R5 and R6 together with the nitrogen atom to which they are attached represent a saturated 3-7 membered heterocyclic ring (with a proviso); are disclosed which are antiinflammatory, antiallergic and immunomodulatory agents. Compositions containing these compounds and processes to prepare these compounds are also disclosed.

Synthesis and structure-activity relationship of some 5- [[[(dialkylamino)alkyl]-1-piperidinyl]acetyl]-10,11-dihydro-5H- benzo[b,e][1,4]diazepin-11-ones as M2-selective antimuscarinics

A series of 5-[[[(dialkylamino)alkyl]-1-piperidinyl]acetyl]-10,11-dihydro- 5H-dibenzo[b,e][1,4]-diazepin-11-ones were prepared as potential M2- selective ligands. The compounds were evaluated for their affinity and selectivity for the muscarinic cholinergic receptor. The best M2-selective antimuscarinic agent studied is 5-[[4-[4-(diethylamino)butyl]-1- piperidinyl]acetyl]-10,11-dihydro-5H-dibenzo[b,e][1,4]diazepin-11-one, which is approximately 10 times more potent at M2 receptors than previously known compounds such as 11-[[4-[4-(diethylamino)butyl]-1-piperidinyl]acetyl]-5,11- dihydro-6H-pyrido[2,3-b][1,4]benzodiazepin-6-one (AQ-RA 741).